GHRS

GH Research PLC [GHRS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

GHRS Stock Summary

Top 10 Correlated ETFs

GHRS

Top 10 Correlated Stocks

GHRS

In the News

GHRS Financial details

Company Rating
-
Market Cap
582.19M
Income
-36.76M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-7.16
Forward P/E
-
PEG
-0.18
P/S
-
P/B
1.34
P/C
-
P/FCF
-9.4
Quick Ratio
26.29
Current Ratio
26.74
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.71
EPS next Y
-
EPS next Q
-
EPS this Y
385.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
100%
-
-
-
-
SMA20
18.88%
SMA50
41.67%
SMA100
48.11%
Inst Own
-
Inst Trans
-
ROA
-18%
ROE
-18%
ROC
-0.17%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.05-14.64
52W High
+2.57%
52W Low
+187.2%
RSI
47.65
Rel Volume
3.16
Avg Volume
129.29K
Volume
408.4K
Perf Week
-13.96%
Perf Month
19.77%
Perf Quarter
6.29%
Perf Half Y
51.16%
-
-
-
-
Beta
0.839
-
-
Volatility
0.34%, 1.95%
Prev Close
2.72%
Price
14.36
Change
-4.07%

Something similar

Top by Market Cap
VFINX
ABEA.DE
VTSAX
NVDA
GOOGL
Top Correlated ETFs
PFXF
BLCN
SATO
DAPP
BLKC
Top Correlated Stocks
MARA
HWKN
0KC4.L
ON
NEE
Similar Market Cap
TCMSX
NMCO
XIOR.BR
MNRO
WIIT.MI

Company Profile

Healthcare Biotechnology
  • Volume Average 129.29K
  • Market Capitalization 582.19M
  • Employee 49
  • CEO Dr. Theis Terwey M.D.
  • Headquarters Dublin,IE
  • IPO Date 2021-06-25
  • Website https://www.ghres.com

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.